Androgen News and Research

RSS

NIH panel recommends name change for polycystic ovary syndrome

An independent panel convened by the National Institutes of Health has concluded that the name of a common hormone disorder in women, polycystic ovary syndrome (PCOS), causes confusion and is a barrier to research progress and effective patient care. The current name focuses on a criterion - ovarian cysts - which is neither necessary nor sufficient to diagnose the syndrome.

24 Jan 2013

FDA approves Ampio’s IND for Optina for treatment of diabetic macular edema

Ampio Pharmaceuticals, Inc. announced today that the FDA has accepted the Company's IND for Optina™ for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina™ 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial.

22 Jan 2013

$ADT increases risk of fracture incidence after treatment completion in men with prostate cancer$

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.

18 Jan 2013

Penis shrinkage caution for prostate cancer patients

Men choosing prostate cancer treatment should be informed about the small risk for penis shrinkage, say US researchers who believe discussing the rare side effect could reduce the chance for patient regret.

7 Jan 2013

Perceived reduction in penis size linked to regrets of prostate cancer treatment choice

A small percentage of men in a prostate cancer study complained that their penis seemed shorter following treatment, with some saying that it interfered with intimate relationships and caused them to regret the type of treatment they chose.

3 Jan 2013

Active surveillance of prostate cancer patients encouraged

Active surveillance is an effective way of monitoring patients with low-risk prostate cancer and is associated with a low risk for systemic progression, say researchers.

31 Dec 2012

Androgen deprivation therapies may have adverse effects in men with precancers

The use of androgen deprivation therapies to prevent precancerous prostate abnormalities developing into aggressive prostate cancer may have adverse effects in men with precancers with specific genetic alterations, according to data from a preclinical study recently published in Cancer Discovery, a journal of the American Association for Cancer Research.

21 Dec 2012

Few alcohol-related story ideas from The Methodist Hospital

The holidays are a time to consume -- food, gifts, and spirits. Here are a few alcohol-related story ideas from The Methodist Hospital. Because alcohol's effects on human physiology are complex, advice about is often contradictory.

20 Dec 2012

ARCHITECT 2nd Generation Testosterone Assay from Abbott

Testosterone is an important androgen hormone in the health and well-being of men and women. Testosterone levels are associated with sexual development, libido, protection against osteoporosis, and cardiovascular health. In men, insufficient testosterone levels (hypogonadism) have been linked to obesity and low libido.

18 Dec 2012

Abiraterone improves outcomes for prostate cancer prior to chemo

Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

17 Dec 2012

Perthes’ disease link to congenital disorders revealed

Researchers have linked Perthes' disease with several congenital conditions, pointing to intra-uterine factors behind the development of the disease.

14 Dec 2012

EZH2 protein enables advanced prostate cancers to spread without stimulation by male hormones

Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.

14 Dec 2012

Epi-marks can lead to homosexuality

Epigenetics - how gene expression is regulated by temporary switches, called epi-marks - appears to be a critical and overlooked factor contributing to the long-standing puzzle of why homosexuality occurs.

12 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

Enzalutamide shows promise in treating triple-negative and estrogen-positive breast cancer

Breast cancers are defined by their drivers - estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each. When breast cancer has an unknown driver, it also has fewer treatment options - this aggressive form of breast cancer without ER, PR or HER2, which was thought not to be driven by hormones, is known as triple negative.

3 Dec 2012

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of the oral, once-daily medication ZYTIGA for use in combination with prednisone or prednisolone in the treatment of metastatic castration-resistant prostate cancer (mCRPC), in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated.

19 Nov 2012

EMUC discusses current and future prospects in imaging for prostate cancer

At the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC) held this weekend in Barcelona, Spain, specialists from radiology, urology, medical oncology and pathology said that new developments and research are already underway but benefits to patients would take some time due to the need for clinical trials, the high cost of funding research and the ability of cancer experts to efficiently take advantage of new insights and approaches, among other challenges.

19 Nov 2012

Study identifies genetic variations as predictors of prostate cancer-related fatigue

Researchers at Moffitt Cancer Center and the University of South Florida have found that men with prostate cancer who receive androgen deprivation therapy may predictably suffer from fatigue if they have single nucleotide polymorphisms in three pro-inflammatory genes. The discovery highlights the importance of personalized medicine, in which therapies are tailored to a patient's genetic profile.

29 Oct 2012

New biomarker measures aggressiveness of primary prostate tumors

Research out of Roswell Park Cancer Institute (RPCI) supports the adoption of a new biomarker to measure the aggressiveness of primary prostate tumors.

24 Oct 2012